Indications & formulation #
Schizophrenia in adults. This reference covers the selected formulation; other indications and products need their own evidence.
Dose reference #
Adult educational reference · Oral tablet · United States. The clinician selects treatment after assessment; this page does not calculate or change a prescription.
Start/target 10–15 mg once daily. Reassess before increases, generally after two weeks. Studied range 10–30 mg/day; higher doses did not improve average efficacy.
Contraindications & important cautions #
Ask about akathisia and new compulsive behavior. Review metabolic effects and dementia-related mortality warning.
Selected important cautions; consult the full product information for all contraindications and warnings.
Adverse effects #
Akathisia, activation and impulse-control problems require inquiry; other antipsychotic cautions remain relevant.
Interactions #
CYP2D6/CYP3A4 modifiers affect exposure; formulation-specific instructions apply to long-acting products.
Monitoring #
Ask about restlessness and new compulsive behaviours; review response, movements, sleep and metabolic findings.
Special populations #
CYP2D6 poor metabolism and CYP2D6/CYP3A4 inhibitors require label-specific reductions; combined modifiers require further adjustment.
Adult scope. Pregnancy, breastfeeding and pediatric use require the exact product’s population-specific guidance and individual assessment.
Discontinuation, restarting & counseling #
Plan reduction and relapse monitoring; oral dosing is not a depot conversion instruction.
Condition-specific prescribing #
Additional indication-specific records retain their own formulation and source context.
Aripiprazole
Adult schizophrenia
Adults · Immediate-release tablets · Oral · United States product labeling
- Starting dose
- 10–15 mg once daily.
- Titration
- Generally wait at least 2 weeks before increasing.
- Treatment range / target
- 10–15 mg/day is the recommended target; trials included up to 30 mg/day.
- Maximum / limits
- 30 mg/day; higher doses within the range were not more effective than 10–15 mg in the cited trials.
- Trial & duration
- Reassess symptoms and function after an adequate trial.
- Monitoring
- Akathisia, activation, impulsive/compulsive behaviors and metabolic parameters.
- Population & organ-function adjustments
- Known CYP2D6 poor metabolizer or strong CYP2D6/CYP3A4 inhibitor: usually half dose; combined strong inhibitors: quarter dose. Follow label for other combinations.
- Important cautions
- Do not mistake activating adverse effects for psychotic relapse. No approval for dementia-related psychosis.
Brands & products #
Historical catalogue observations. Prices and catalogue presence do not establish current availability or Indian approval.
Reference coverage #
Structured summary of selected adult uses, not an exhaustive monograph. Indian product authorization and local prescribing requirements have not been reconciled.
References · 2
- Aripiprazole — Oral tablet — selected prescribing information · United States · Checked 2026-10-27 · Selected formulation: Oral tablet · Supports indications, dose, cautions, adverse effects, interactions, monitoring, special populations and stopping. Source sections: Indications and usage; Dosage and administration; Contraindications; warnings and precautions; Use in specific populations; patient counseling
- Aripiprazole tablets — product label, sections 2, 5 and 8 · United States · Checked 2026-10-26 · Supports: Aripiprazole — Adult schizophrenia (Immediate-release tablets)